Metyrapone
SIGMA/M2696 - ≥98% (HPLC), solid
Synonym: 2-
CAS Number: 54-36-4
Empirical Formula (Hill Notation): C14H14N2O
Molecular Weight: 226.27
EC Number: 200-206-2
MDL Number: MFCD00006397
Linear Formula: C14H14N2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | solid |
| InChI | 1S/C14H14N2O/c1-14(2,12-6 |
| InChI key | FJLBFSROUSIWMA-UHFFFAOYSA |
| mp | 52-55 °C (lit.) |
| originator | Novartis |
| Quality Level | 100  |
| shipped in | ambient |
| SMILES string | CC(C)(c1cccnc1)C(=O)c2ccc |
| solubility | DMSO: >20 mg/mL |
| H2O: <2 mg/mL | |
| sterility | non-sterile |
| storage temp. | room temp |
| technique(s) | toxicology assay: suitable |
| Biochem/physiol Actions: | Metyrapone is a glucocorticoid synthesis inhibitor; a standard in assessing adrenal gland function especially in response to stress, as well as pituitary gland function. In addition to acting as a glucocorticoid synthesis inhibitor, Metyrapone also inhibits cytochrome P450-mediated prostaglandin ω/ω-1 hydroxylase activity and impairs learning and memory. Data shows results in activation of the sleep EEG and a robust decrease in quantitative delta sleep. |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 - H315 - H319 - H335 |
| Precautionary statements | P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| mp | 52-55 °C (lit.) |
| Storage Temp. | room temp |
| UNSPSC | 51111800 |